Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) will release its financial results for Q4 and the full year of fiscal 2021 on October 21, 2021, prior to market opening. A conference call is scheduled for 8:30 a.m. EDT to discuss the financial outcomes, business strategy, and regulatory processes. The call can be accessed by participants in the U.S. and the U.K. via designated toll-free numbers. Renalytix focuses on advancing kidney health through innovative solutions, including the FDA-designated Breakthrough product, KidneyIntelX™.

Positive

• Scheduled release of Q4 and full-year fiscal 2021 results may provide insights into financial health.
• KidneyIntelX™ has received Breakthrough Designation from the FDA, enhancing its market potential.

Negative

• None.

LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (EDT) / 1:30 p.m. (BST).

Conference Call Details:
US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551
US/Canada Participant International Dial-In Number: (914) 987-7290
United Kingdom International Dial-In Number: 0800 0288 438
United Kingdom Local Dial-In Number: 0203 1070 289
Conference ID:6364722

Webcast Registration link:  https://edge.media-server.com/mmc/p/r4ezp7bk

For further information, please contact:

Renalytix plc	www.renalytix.com
James McCullough, CEO	Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)	Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)	Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne	Mob: 07980 541 893 / 07584 391 303
CapComm Partners	Tel: 415-389-6400 or investors@renalytix.com
Peter DeNardo

About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

FAQ

What date will Renalytix release its Q4 and full-year financial results for 2021?

Renalytix will release its financial results on October 21, 2021.

What time is the Renalytix financial results conference call?

The conference call is scheduled for 8:30 a.m. EDT.

What is the significance of KidneyIntelX™ for Renalytix?

KidneyIntelX™ is designed to improve kidney disease prognosis and has received Breakthrough Designation from the FDA.

Where can I find more information about Renalytix?

For more information, visit their website at www.renalytix.com.